NIH Translational Science Center Becomes A (Cash-limited) Reality
Executive Summary
NIH receives more than one-half billion dollars to finance activities of the National Center for Advancing Translational Science, which came into being when President Obama signed a consolidated fiscal 2012 appropriations bill Dec. 23. House and Senate members who negotiated the final bill cautioned that NCATS’ efforts to find ways to speed up drug development should not inhibit private efforts in the same arena.
You may also be interested in...
US FDA Exploring Consortium To Develop Treatments For ‘Economically Infeasible’ Cancer Indications
The FDA could partner with industry, academia and advocacy groups to speed development of novel treatments for cancers that are not commercially viable.
Pfizer CTI Research Network Expands With NIH Collaboration
The partnership, announced Dec. 4, marks the first time a U.S. government agency has entered into a collaborative arrangement to conduct research through Pfizer’s Centers for Therapeutic Innovation network.
NIH Drug Development Strategy Gets First Candidate Through Valley Of Death
AesRx and its potential treatment for sickle cell disease are acquired by Baxter International, a measure of validation for the NCATS model of de-risking product development for rare and neglected diseases.